MALT lymphomas are generally indolent, that is, they grow slowly and cause little in the way of symptoms.
MALT lymphomas are then recognized as areas of inflammation or ulceration within the stomach.
It is not known if infectious agents also cause MALT lymphomas outside of the stomach.
The indolent nature of most MALT lymphomas means that the majority of patients are diagnosed at early stages with relatively nonspecific symptoms.
While the H. pylori infections are associated with this and other gastric disease, the eradication of H pylori in asymptomatic individuals is not currently recommended for prevention of MALT lymphomas or gastric cancer.
MALT lymphomas occur at a frequency of about 1.5 per 100,000 people per year in the United States and account for about 10% of all non-Hodgkin's lymphomas.
MALT lymphomas are solid tumors that originate from cancerous growth of immune cells that are recruited to secretory tissue such as the gastrointestinal tract, salivary glands, lungs, and the thyroid gland.
In the stomach they are associated, in greater than 90% of all cases, with the bacteria called Helicobacter pylori (H. pylori).
Those MALT lymphomas that arise in the stomach in response to H. pylori infections are generally successfully treated with antibiotics, which eliminate the bacteria.
it is standard practice that patients presenting with MALT lymphomas should be evaluated in a similar manner to individuals with nodal lymphomas, the more common type of lymphoma that originates at sites within the lymphoid system.
In some cases, such as in the thyroid, MALT lymphomas seem to arise in patients who have autoimmune diseases, which make their immune systems treat their own tissue as foreign or antigenic.
Effective treatment for these lymphomas has been achieved with local radiation, chemotherapy, and/or interferon.
The frequency varies among different populations. For example, in parts of Italy the frequency of MALT lymphomas is as high as 13 per 100,000 people per year.